{"id":"subconjunctival-avastin","safety":{"commonSideEffects":[{"rate":null,"effect":"Conjunctival injection/hyperemia"},{"rate":null,"effect":"Subconjunctival hemorrhage"},{"rate":null,"effect":"Eye pain or discomfort"},{"rate":null,"effect":"Anterior chamber inflammation"},{"rate":null,"effect":"Endophthalmitis (rare)"}]},"_chembl":{"chemblId":"CHEMBL1201583","moleculeType":"Antibody"},"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"Bevacizumab is a monoclonal antibody that binds to and neutralizes VEGF, a key driver of pathological neovascularization and vascular permeability. When administered subconjunctivally (under the conjunctiva), it locally suppresses VEGF signaling to reduce edema, hemorrhage, and abnormal vessel growth in retinal and choroidal diseases. This off-label use leverages the drug's anti-angiogenic properties to treat various ocular conditions without systemic exposure.","oneSentence":"Avastin (bevacizumab) inhibits vascular endothelial growth factor (VEGF) to reduce abnormal blood vessel formation and leakage in the eye.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:36:33.907Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Age-related macular degeneration (wet AMD)"},{"name":"Diabetic macular edema"},{"name":"Retinal vein occlusion"},{"name":"Proliferative diabetic retinopathy"}]},"trialDetails":[{"nctId":"NCT06983704","phase":"EARLY_PHASE1","title":"Assessing Combined Bevacizumab-Mitomycin C Use During Ahmed Valve Revision in Recurrent Pediatric Glaucoma","status":"COMPLETED","sponsor":"Benha University","startDate":"2024-02-09","conditions":"Pediatric Glaucoma","enrollment":50},{"nctId":"NCT00555594","phase":"PHASE2, PHASE3","title":"Prospective Study to Determine the Effect of Subconjunctival Bevacizumab (AVASTIN) in Corneal Neovascularization","status":"COMPLETED","sponsor":"Asociación para Evitar la Ceguera en México","startDate":"2006-09","conditions":"Corneal Neovascularization","enrollment":18},{"nctId":"NCT05314673","phase":"PHASE4","title":"Preoperative Bevacizumab Injection in Primary Pterygium in Tunisian Patients","status":"COMPLETED","sponsor":"University Hospital Fattouma Bourguiba","startDate":"2019-01-01","conditions":"Pterygium","enrollment":60},{"nctId":"NCT04827836","phase":"NA","title":"Pain Control and Subconjunctival Hemorrhage Size After Intravitreal Injection","status":"COMPLETED","sponsor":"Wolfson Medical Center","startDate":"2021-07-11","conditions":"Intravitreal Injection, Pain, Subconjunctival Hemorrhage","enrollment":100},{"nctId":"NCT02767219","phase":"PHASE3","title":"The Use of Bevacizumab as a Modulator of Wound Healing Following Trabeculectomy Surgery","status":"COMPLETED","sponsor":"Moorfields Eye Hospital NHS Foundation Trust","startDate":"2016-05","conditions":"Glaucoma","enrollment":6},{"nctId":"NCT03037736","phase":"PHASE4","title":"Outpatient Performed Pterygium Surgery Study","status":"WITHDRAWN","sponsor":"University of California, San Francisco","startDate":"2020-03-01","conditions":"Pterygium of Conjunctiva and Cornea","enrollment":""},{"nctId":"NCT01996826","phase":"PHASE1, PHASE2","title":"A Multi-Center Study of the Safety and Efficacy of Bevacizumab in High-Risk Corneal Transplant Survival","status":"COMPLETED","sponsor":"Reza Dana, MD","startDate":"2014-04","conditions":"Corneal Neovascularization, Corneal Graft Failure","enrollment":75},{"nctId":"NCT01501760","phase":"PHASE3","title":"Efficacy and Safety Study of Avastin to Treat Neovascularisation of the Cornea","status":"COMPLETED","sponsor":"University Hospital, Limoges","startDate":"2012-05-13","conditions":"Corneal Newvessels","enrollment":38},{"nctId":"NCT01976923","phase":"PHASE3","title":"Pre-Operative Intravitreal Bevacizumab for Tractional Retinal Detachment Secondary to Proliferative Diabetic Retinopathy","status":"COMPLETED","sponsor":"J. Fernando Arevalo, MD FACS","startDate":"2013-11","conditions":"Tractional Retinal Detachment Secondary to Proliferative Diabetic Retinopathy","enrollment":224},{"nctId":"NCT00853073","phase":"PHASE2, PHASE3","title":"Does Adding Bevacizumab Therapy in Glaucoma Surgery Improve the Success of Needle Bleb Revisions?","status":"COMPLETED","sponsor":"Wills Eye","startDate":"2009-02","conditions":"Glaucoma","enrollment":63},{"nctId":"NCT01072357","phase":"PHASE1, PHASE2","title":"Safety and Efficacy of Bevacizumab in High-Risk Corneal Transplant Survival","status":"COMPLETED","sponsor":"Reza Dana, MD","startDate":"2009-12","conditions":"Corneal Neovascularization, Corneal Graft Failure","enrollment":30},{"nctId":"NCT02007174","phase":"","title":"Bevacizumab Injection for Recurrent Pterygium","status":"COMPLETED","sponsor":"Instituto de Oftalmología Fundación Conde de Valenciana","startDate":"2012-03","conditions":"Recurrent Pterygium","enrollment":38},{"nctId":"NCT02530801","phase":"PHASE4","title":"Strategies for Management of Recurrent Pterygium","status":"UNKNOWN","sponsor":"University of Nottingham","startDate":"2017-01","conditions":"Recurrent Pterygium","enrollment":25},{"nctId":"NCT01774474","phase":"PHASE3","title":"PRevention of Macular EDema After Cataract Surgery","status":"COMPLETED","sponsor":"Maastricht University Medical Center","startDate":"2013-07-10","conditions":"Cystoid Macular Edema, Cataract, Diabetes Mellitus","enrollment":1127},{"nctId":"NCT02901236","phase":"PHASE2, PHASE3","title":"Bevacizumab Versus Mitomycin C as Trabeculectomy Adjuvant in Uncontrolled Glaucoma","status":"COMPLETED","sponsor":"Athens Vision Eye Institute","startDate":"2014-01","conditions":"Glaucoma","enrollment":40},{"nctId":"NCT02796183","phase":"NA","title":"The Efficacy of Subconjunctival Bevacizumab in Diabetic Macular Edema","status":"COMPLETED","sponsor":"Neon Hospital","startDate":"2015-01","conditions":"Diabetic Macular Edema","enrollment":20},{"nctId":"NCT02594423","phase":"PHASE4","title":"Strategies for Management of Corneal Neovascularisation","status":"UNKNOWN","sponsor":"University of Nottingham","startDate":"2015-12","conditions":"Corneal Neovascularisation","enrollment":40},{"nctId":"NCT01640171","phase":"NA","title":"Anesthesia Preference for Intravitreal Injection: Topical or Subconjunctival","status":"COMPLETED","sponsor":"Retina Vitreous Associates of Florida","startDate":"2012-07","conditions":"Age-related Macular Degeneration, Central Retinal Vein Occlusion, Diabetic Macular Edema","enrollment":57},{"nctId":"NCT01686529","phase":"PHASE1","title":"Bevacizumab for Primary Pterygium Treatment","status":"COMPLETED","sponsor":"Instituto de Oftalmología Fundación Conde de Valenciana","startDate":"2010-03","conditions":"Pterygium","enrollment":49},{"nctId":"NCT01744756","phase":"PHASE2, PHASE3","title":"Subconjunctival Bevacizumab and Recurrent Pterygium","status":"COMPLETED","sponsor":"Instituto de Olhos de Goiania","startDate":"2012-02","conditions":"Recurrent Pterygium","enrollment":36},{"nctId":"NCT00797303","phase":"PHASE4","title":"The Effect of Bevacizumab on Corneal Neovascularization","status":"COMPLETED","sponsor":"Instituto de Olhos de Goiania","startDate":"2006-01","conditions":"Corneal Neovascularization","enrollment":8},{"nctId":"NCT01425112","phase":"NA","title":"Comparison of Subconjuctival Versus Topical Bevacizumab as Adjunct Therapy to Trabeculectomy","status":"COMPLETED","sponsor":"Sudhalkar Eye Hospital","startDate":"2007-12","conditions":"Complications of Treatment, Progression","enrollment":180},{"nctId":"NCT01310764","phase":"NA","title":"Trabeculectomy With Subconjunctival Bevacizumab Injection","status":"COMPLETED","sponsor":"Rassoul Akram Hospital","startDate":"2009-04","conditions":"Glaucoma","enrollment":36},{"nctId":"NCT01288404","phase":"NA","title":"Randomized Controlled Trial of Subconjunctival Bevacizumab Injection in Impending Recurrent Pterygium","status":"COMPLETED","sponsor":"Ramathibodi Hospital","startDate":"2008-01","conditions":"Pterygium of the Conjunctiva and Cornea","enrollment":80},{"nctId":"NCT01122966","phase":"PHASE2, PHASE3","title":"The Effect of Bevacizumab on the Trabeculectomy","status":"UNKNOWN","sponsor":"Samsung Medical Center","startDate":"2010-03","conditions":"Glaucoma","enrollment":40},{"nctId":"NCT01128699","phase":"PHASE3","title":"Ahmed Valve Glaucoma Implant With Adjunctive Subconjunctival Bevacizumab in Refractory Glaucoma","status":"UNKNOWN","sponsor":"Vanak Eye Surgery Center","startDate":"2010-05","conditions":"Refractory Glaucoma","enrollment":40},{"nctId":"NCT00992849","phase":"PHASE2","title":"Bevacizumab for the Treatment of Corneal Neovascularization","status":"UNKNOWN","sponsor":"Chang Gung Memorial Hospital","startDate":"2009-05","conditions":"Corneal Neovascularization","enrollment":10},{"nctId":"NCT00854529","phase":"PHASE2","title":"Subconjunctival Bevacizumab Effect on Bleb Vascularity","status":"UNKNOWN","sponsor":"Rabin Medical Center","startDate":"2009-04","conditions":"Bleb Vascularity, Bleb Fibrosis, Trabeculectomy Failure","enrollment":60},{"nctId":"NCT00815594","phase":"PHASE4","title":"Bleb Vascularity Change After Subconjunctival Injection Bevacizumab","status":"UNKNOWN","sponsor":"Capital Medical University","startDate":"2008-12","conditions":"Bleb Vascularity, Conjunctival Scarring","enrollment":30},{"nctId":"NCT00681603","phase":"NA","title":"Safety and Effectiveness of Subconjunctival Injection of Bevacizumab in the Treatment of Corneal Neovasculization","status":"COMPLETED","sponsor":"National Taiwan University Hospital","startDate":"2007-08","conditions":"Lipid Keratopathy, Penetrating Keratoplasty, Herpetic Keratopathy","enrollment":13},{"nctId":"NCT00384631","phase":"NA","title":"Intravitreal Bevacizumab for Neovascular Glaucoma","status":"COMPLETED","sponsor":"Shahid Beheshti University of Medical Sciences","startDate":"2006-04","conditions":"Neovascular, Glaucoma","enrollment":26},{"nctId":"NCT00468429","phase":"PHASE4","title":"Subconjunctival Bevacizumab to Prevent Bleb Failure After Glaucoma Filtration Surgery","status":"UNKNOWN","sponsor":"Grewal Eye Institute","startDate":"2007-05","conditions":"Glaucoma","enrollment":40}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Subconjunctival Avastin","genericName":"Subconjunctival Avastin","companyName":"Vanak Eye Surgery Center","companyId":"vanak-eye-surgery-center","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Subconjunctival Avastin, also known as bevacizumab, is an antibody that inhibits vascular endothelial growth factor A, a protein involved in the formation of new blood vessels. It has been studied in clinical trials for various conditions, including Diabetic Macular Edema, Neovascular, Glaucoma, Bleb Vascularity, and Bleb Fibrosis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}